Cat.No. : CSC-RO0103 Host Cell: Ba/F3
Size: >1x10^6 frozen cells/vial, 1 mL Stability: Stable in culture over a minimum of 10 passages
| Cat. No. | CSC-RO0103 |
| Description | Ba/F3-ERBB2 cell line is a stably transfected cell line which expresses human erb-b2 receptor tyrosine kinase 2 (ERBB2). |
| Target Gene | ERBB2 |
| Gene Species | Homo sapiens (Human) |
| Host Cell | Ba/F3 |
| Host Cell Species | Mus musculus (Mouse) |
| Stability | Stable in culture over a minimum of 10 passages |
| Application | Drug screening and biological assays |
| Growth Conditions | 37 °C, 5% CO2 |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Shipping | Dry ice |
| Size | >1x10^6 frozen cells/vial, 1 mL |
| Biosafety Level | 2 |
| Thawing & Subculturing Instructions | 1. Thaw cells by gently swirling in a 37°C water bath. To limit contamination, do not submerge the O-ring and cap. 2. When cells are ~70% thawed (~1 min), transfer the vial into a biosafety cabinet, and wipe the surface with 70% ethanol. Allow tube to dry completely. 3. Transfer the cells gently into a 15 mL conical tube containing 10 mL of pre-warmed culture medium (without antibiotic selection marker). Centrifuge cells at ~125 x g for 5~7 min. 4. Remove supernatant without disturbing the pellet, and resuspend cells in 1 mL culture medium (without antibiotic selection marker). Transfer cells to a 6-well plate containing ~2 mL pre-warmed growth medium (without antibiotic selection marker) or a T25 flask containing 5 mL pre-warmed culture medium (without antibiotic selection marker). 5. Incubate the culture at 37°C with 5% CO2. 6. Subculture: split saturated culture 1:4 ~ 1:6 every 3 days; seed out at about 1~3 x 10^5 cells/mL. |
| Growth Properties | Suspension, round |
| Freeze Medium | Frozen with 70% medium, 20% FBS, 10% DMSO |
| Freezing Instructions | Cells are recommended to generate additional frozen stocks at early passages. Frozen stocks should be preserved in a designated cryopreservation medium or in 70% RPMI 1640 + 20% FBS + 10% DMSO (without antibiotic selection marker). 1. Prepare the freezing medium (70% RPMI 1640 + 20% FBS + 10% DMSO, without antibiotic selection marker) fresh immediately before use. 2. Keep the freezing medium on ice and label cryovials. 3. Transfer cells to a sterile, conical centrifuge tube, and count the cells. 4. Centrifuge the cells at 250 x g for 5 minutes at room temperature and carefully aspirate off the medium. 5. Resuspend the cells at a density of at least 3 x10^6 cells/ml in chilled freezing medium. 6. Aliquot 1 ml of the cell suspension into each cryovial. 7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer. 8. Transfer vials to liquid nitrogen for long-term storage. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
A: The Human ERBB2 Stable Cell Line-Ba/F3 allows for the investigation of multiple signaling pathways downstream of the ERBB2 receptor, including the PI3K/AKT, MAPK/ERK, and PLCγ pathways. The overexpression of ERBB2 in these cells leads to the activation of these pathways, which play crucial roles in cell growth, survival, and differentiation. By utilizing this cell line, researchers can study the effects of various inhibitors or activators on these pathways, providing insights into the mechanisms of ERBB2-driven cell signaling and potential targets for cancer therapy.
A: The Human ERBB2 Stable Cell Line-Ba/F3 is an excellent model for evaluating the efficacy of ERBB2-targeted therapies due to its reliance on ERBB2 signaling for growth and survival. Researchers can treat these cells with different concentrations of ERBB2-targeted agents and assess their effects on cell viability, proliferation, and signaling. This can provide valuable information on the potency and specificity of these therapeutics, as well as help optimize dosing and treatment regimens for clinical applications.
A: When using the Human ERBB2 Stable Cell Line-Ba/F3 to study the impact of genetic mutations on ERBB2 function, it is important to introduce these mutations using precise genetic engineering techniques, such as CRISPR/Cas9 or site-directed mutagenesis. Researchers must also consider the potential off-target effects of these techniques and validate the impact of the mutations on ERBB2 activity and downstream signaling pathways through various assays, including Western blotting, immunoprecipitation, and reporter gene assays.
A: The Human ERBB2 Stable Cell Line-Ba/F3 can be used to perform co-immunoprecipitation experiments to identify novel interactors of the ERBB2 receptor. By expressing tagged versions of ERBB2 or its potential interactors, researchers can isolate protein complexes and identify novel binding partners. Further functional studies, such as knockdown or overexpression experiments, can then be conducted to determine the roles of these interactors in cellular processes, such as signal transduction, cell cycle regulation, and apoptosis.
A: The Human ERBB2 Stable Cell Line-Ba/F3 can be employed to study the development of resistance to ERBB2-targeted therapies by long-term exposure to these agents, leading to the selection of resistant cell sublines. These resistant cells can then be analyzed to identify the molecular mechanisms underlying the resistance, such as alterations in ERBB2 expression levels, activation of alternative signaling pathways, or changes in drug metabolism. This information can be used to develop strategies to overcome or prevent resistance, ultimately improving the efficacy of ERBB2-targeted therapies.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
The Human ERBB2 Stable Cell Line - Ba/F3 enables enhanced study of the ERBB2 protein, a key receptor tyrosine kinase involved in cell growth and differentiation. This cell line provides a consistent and controlled environment to explore ERBB2's role in oncogenic processes, making it invaluable for cancer research.
By stably expressing ERBB2, the Human ERBB2 Stable Cell Line - Ba/F3 assists in elucidating signaling pathways that are activated by ERBB2 engagement. This is critical for understanding the molecular mechanisms of diseases where ERBB2 is implicated, such as breast and ovarian cancers.
The consistent expression of ERBB2 in the Human ERBB2 Stable Cell Line - Ba/F3 enhances the reproducibility of experimental results. This reproducibility is crucial for studies that require precise, reliable data, particularly in preclinical cancer research.
The Human ERBB2 Stable Cell Line - Ba/F3 is versatile, suitable for a range of functional assays including proliferation, apoptosis, and cell signaling studies. This versatility makes it an essential tool for comprehensive analysis of ERBB2 functions and its contributions to pathological conditions.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
